|
1
|
Endo-Munoz L, Evdokiou A and Saunders NA:
The role of osteoclasts and tumour-associated macrophages in
osteosarcoma metastasis. Biochim Biophys Acta. 1826:434–442.
2012.PubMed/NCBI
|
|
2
|
Poletajew S, Fus L and Wasiutyński A:
Current concepts on pathogenesis and biology of metastatic
osteosarcoma tumours. Ortop Traumatol Rehabil. 13:537–545. 2011.In
English, Polish. View Article : Google Scholar
|
|
3
|
Tanzawa H, Uchiyama S and Sato K:
Statistical observation of osteosarcoma of the maxillofacial region
in Japan. Analysis of 114 Japanese cases reported between 1930 and
1989. Oral Surg Oral Med Oral Pathol. 72:444–448. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee YY, Van Tassel P, Nauert C, Raymond AK
and Edeiken J: Craniofacial osteosarcomas: plain film, CT, and MR
findings in 46 cases. AJR Am J Roentgenol. 150:1397–1402. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harting MT and Blakely ML: Management of
osteosarcoma pulmonary metastases. Semin Pediatr Surg. 15:25–29.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu AN, Zhu ZH, Chang SJ and Hang XS:
Twist expression associated with the epithelial-mesenchymal
transition in gastric cancer. Mol Cell Biochem. 367:195–203. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cui J, Wang W, Li Z, Zhang Z, Wu B and
Zeng L: Epigenetic changes in osteosarcoma. Bull Cancer.
98:E62–E68. 2011.PubMed/NCBI
|
|
8
|
Chen YG, Wang Q, Lin SL, Chang CD, Chuang
J and Ying SY: Activin signaling and its role in regulation of cell
proliferation, apoptosis, and carcinogenesis. Exp Biol Med
(Maywood). 231:534–544. 2006.
|
|
9
|
Sulyok S, Wankell M, Alzheimer C and
Werner S: Activin: an important regulator of wound repair,
fibrosis, and neuroprotection. Mol Cell Endocrinol. 225:127–132.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antsiferova M and Werner S: The bright and
the dark sides of activin in wound healing and cancer. J Cell Sci.
125:3929–3937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kypriotou M, Rivero D, Haller S, et al:
Activin A inhibits antigen-induced allergy in murine epicutaneous
sensitization. Front Immunol. 4:2462013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neel JC and Lebrun JJ: Activin and TGFβ
regulate expression of the microRNA-181 family to promote cell
migration and invasion in breast cancer cells. Cell Signal.
25:1556–1566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deli A, Kreidl E, Santifaller S, et al:
Activins and activin antagonists in hepatocellular carcinoma. World
J Gastroenterol. 14:1699–1709. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsuo SE, Leoni SG, Colquhoun A and
Kimura ET: Transforming growth factor-beta1 and activin A generate
anti-proliferative signaling in thyroid cancer cells. J Endocrinol.
190:141–150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaneda H, Arao T, Matsumoto K, et al:
Activin A inhibits vascular endothelial cell growth and suppresses
tumour angiogenesis in gastric cancer. Br J Cancer. 105:1210–1217.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Burdette JE, Jeruss JS, Kurley SJ, Lee EJ
and Woodruff TK: Activin A mediates growth inhibition and cell
cycle arrest through Smads in human breast cancer cells. Cancer
Res. 65:7968–7975. 2005.PubMed/NCBI
|
|
17
|
Ramachandran A, Marshall ES, Love DR,
Baguley BC and Shelling AN: Activin is a potent growth suppressor
of epithelial ovarian cancer cells. Cancer Lett. 285:157–165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ottley E and Gold E: Insensitivity to the
growth inhibitory effects of activin A: an acquired capability in
prostate cancer progression. Cytokine Growth Factor Rev.
23:119–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang KP, Kao HK, Liang Y, et al:
Overexpression of activin A in oral squamous cell carcinoma:
association with poor prognosis and tumour progression. Ann Surg
Oncol. 17:1945–1956. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoda MA, Munzker J, Ghanim B, et al:
Suppression of activin A signals inhibits growth of malignant
pleural mesothelioma cells. Br J Cancer. 107:1978–1986. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Marino FE, Risbridger G and Gold E: The
therapeutic potential of blocking the activin signalling pathway.
Cytokine Growth Factor Rev. 24:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshinaga K, Mimori K, Inoue H, et al:
Activin A enhances MMP-7 activity via the transcription factor AP-1
in an esophageal squamous cell carcinoma cell line. Int J Oncol.
33:453–459. 2008.PubMed/NCBI
|
|
23
|
Antsiferova M, Huber M, Meyer M, et al:
Activin enhances skin tumourigenesis and malignant progression by
inducing a pro-tumourigenic immune cell response. Nat Commun.
2:5762011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terpos E, Kastritis E, Christoulas D, et
al: Circulating activin A is elevated in patients with advanced
multiple myeloma and correlates with extensive bone involvement and
inferior survival; no alterations post-lenalidomide and
dexamethasone therapy. Ann Oncol. 23:2681–2686. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Wang HJ, Ruan HJ, He XJ, et al:
MicroRNA-101 is down-regulated in gastric cancer and involved in
cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Phillips DJ, Jones KL, Clarke IJ,
Scheerlinck JP and de Kretser DM: Activin A: from sometime
reproductive factor to genuine cytokine. Vet Immunol Immunopathol.
108:23–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sobral LM, Bufalino A, Lopes MA, Graner E,
Salo T and Coletta RD: Myofibroblasts in the stroma of oral cancer
promote tumorigenesis via secretion of activin A. Oral Oncol.
47:840–846. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kang HY, Huang HY, Hsieh CY, et al:
Activin A enhances prostate cancer cell migration through
activation of androgen receptor and is overexpressed in metastatic
prostate cancer. J Bone Miner Res. 24:1180–1193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Le Bras GF, Allison GL, Richards NF,
Ansari SS, Washington MK and Andl CD: CD44 upregulation in
E-cadherin-negative esophageal cancers results in cell invasion.
PloS one. 6:e270632011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Incorvaia L, Badalamenti G, Rini G, et al:
MMP-2, MMP-9 and activin A blood levels in patients with breast
cancer or prostate cancer metastatic to the bone. Anticancer Res.
27:1519–1525. 2007.PubMed/NCBI
|
|
32
|
Jianwei Z, Fan L, Xiancheng L, Enzhong B,
Shuai L and Can L: MicroRNA 181a improves proliferation and
invasion, suppresses apoptosis of osteosarcoma cell. Tumour Biol.
34:3331–3337. 2013. View Article : Google Scholar : PubMed/NCBI
|
